SCHEMBL30761771

CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](N)CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C)[C@@H](C)CC

nearest known ligand 0.67

Predicted protein targets (top 12)

	gene	UniProt	supporting neighbours	confidence
▸	BACE1	P56817	1/20	0.58

▸	CRHR1	P34998	1/20	0.58

▸	CRHR2	Q13324	1/20	0.58

▸	CALCR	P30988	3/20	0.57

▸	NPY2R	P49146	8/20	0.55

▸	NPY4R	P50391	8/20	0.55

▸	NPY5R	Q15761	8/20	0.55

▸	NPY1R	P25929	6/20	0.55

▸	AGTR2	P50052	3/20	0.53

▸	AGTR1	P30556	2/20	0.53

▸	CXCL8	P10145	2/20	0.53

▸	TFPI	P10646	1/20	0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30363005	1.00	BACE1 (0.58)	BACE1CRHR1CRHR2CALCRNPY2R
SCHEMBL30362923	1.00	BACE1 (0.58)	BACE1CRHR1CRHR2CALCRNPY2R
SCHEMBL29693043	1.00	BACE1 (0.58)	BACE1CRHR1CRHR2CALCRNPY2R
SCHEMBL30362943	1.00	BACE1 (0.58)	BACE1CRHR1CRHR2CALCRNPY2R
SCHEMBL30363072	1.00	BACE1 (0.58)	BACE1CRHR1CRHR2CALCRNPY2R
SCHEMBL29626845	1.00	BACE1 (0.58)	BACE1CRHR1CRHR2CALCRNPY2R
SCHEMBL30362994	0.99	BACE1 (0.58)	BACE1CRHR1CRHR2CALCRNPY2R
SCHEMBL30363074	0.99	BACE1 (0.58)	BACE1CRHR1CRHR2CALCRNPY2R
SCHEMBL29501059	0.99	BACE1 (0.59)	BACE1CRHR1CRHR2CALCRNPY2R
SCHEMBL30362874	0.99	CALCR (0.58)	BACE1CRHR1CRHR2CALCRNPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
CN-122081247-A	Oncolytic vaccinia virus and recombinant viruses and methods of use thereof	—	2026-05-26	—	—	CN	disclosed
US-20260137773-A1	ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF	VIROMISSILE, INC. (US)	2026-05-21	—	—	US	disclosed
US-20260097116-A1	ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF	VIROMISSILE, INC. (US)	2026-04-09	—	—	US	disclosed
EP-4551240-A1	ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF	Viromissile, Inc. (US)	2025-05-14	—	—	EP	disclosed
US-20240033347-A1	ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF	VIROMISSILE, INC. (US)	2024-02-01	—	—	US	disclosed
WO-2024011250-A1	ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF	VIROMISSILE, INC. (US)	2024-01-11	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20260097116-A1	ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF	IRF3, IFNAR1, CXCL10	BACE1 3984/4885CRHR1 1818/4885CRHR2 1535/4885
US-20260137773-A1	ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF	CASP9, TP53, CASP2	BACE1 2398/4885CRHR1 4788/4885CRHR2 4748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.